Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

55514

Sigma-Aldrich

BioStab Antibody Stabilizer

Synonym(s):

Antibody Stabilizer BioStab

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352204
NACRES:
NA.25

technique(s)

HPLC: suitable

Quality Level

impurities

DNases, none detected
RNases, none detected
phosphatases, none detected
proteases, none detected

suitability

corresponds for identity (HPLC)

storage temp.

2-8°C

Application

Antibodies can be protected from degradation effects using BioStab Antibody Stabilizer. The addition of BioStab Antibody Stabilizer increases life-time and the coating rates of the antibodies. BioStab Antibody Stabilizer can be used in ELISA, Western Blotting, Immunohistochemistry and any other applications which require marker or biotinylated antibodies. This stabilizer contains a minimum amount of a surfactant.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

55514-250ML-F:
55514-1L-F:
55514-250ML-BULK-F:
55514-1L-BULK-F:


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jarem Edwards et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(11), 3247-3258 (2019-02-20)
Immunotherapies targeting costimulating and coinhibitory checkpoint receptors beyond PD-1 and CTLA-4 have entered clinical trials. Little is known about the relative abundance, coexpression, and immune cells enriched for each specific drug target, limiting understanding of the biological basis of potential
Lakshman N Subbaraman et al.
Optometry and vision science : official publication of the American Academy of Optometry, 82(3), 209-214 (2005-03-16)
Lysozyme deposits extracted from lotrafilcon silicone hydrogel (SH) contact lens materials demonstrate a loss in total mass as a function of storage time when assessed by Western blotting. This loss represents a potential source of error when quantifying total lysozyme
Eduardo P Melo et al.
Current protein & peptide science, 11(8), 744-751 (2011-01-18)
Biomedical applications of osmolytes, including stabilization of protein-based pharmaceutics, preservation of living biological material and potential therapeutic prescription in vivo, are intimately related to the fact that osmolytes favour the native structure of proteins. The shift towards the native structure
E Ron et al.
Journal of immunological methods, 180(2), 237-245 (1995-03-27)
A two step simple procedure for antibody stabilization in soluble form was developed. The antibody is first treated with low molecular weight polyaldehyde (polyglutaraldehyde). Following removal of non-bound polyaldehyde the antibody-polyaldehyde conjugate is crosslinked by polyamine (alkyl amine derivative of
Tim Serno et al.
Advanced drug delivery reviews, 63(13), 1086-1106 (2011-09-13)
Aggregation is arguably the biggest challenge for the development of stable formulations and robust manufacturing processes of therapeutic proteins. In search of novel excipients inhibiting protein aggregation, cyclodextrins and their derivatives have been under examination for use in parenteral protein

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service